Try our mobile app

Switch to company model in "Rising Stars" logic    *

General information

Country: UNITED STATES

Sector: Diagnostics and Research

Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment produces and sells research model strains primarily purpose-bred rats and mice for use by researchers. It also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification of a druggable target through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as bioanalysis, drug metabolism, pharmacokinetics, safety pharmacology, toxicology, and pathology services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile biopharmaceuticals, and consumer products. It also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pat...
Website: criver.com


  • Bad financial results growth rate -50.3% (average between last period year over year growth for revenue and EBITDA), there is slowdown compared to average historical growth rates (-0.3%)
  • Dividend yield for the last twelve months 0.0%
  • Free cash flow yield 0.0% (LTM)
  • Share price is 122.9% higher than minimum and 18.7% lower than maximum for the last 3 years
  • The company is overvalued by EV / LTM EBITDA multiple compared to target level (23.1x vs 14.2x)
  • Fundamental value created in LTM (estimate)

Key Financials (Download financials)

Ticker: CRL
Share price, USD:  (0.0%)222.35
year average price 165.70  


year start price 151.99 2025-02-14

min close price 99.75 2025-04-11

max close price 226.77 2026-01-21

current price 222.35 2026-02-13
Common stocks: 51 380 000

Dividend Yield:  0.0%
EV / LTM EBITDA: 23.1x
EV / Sales: 3.4x
Margin (EBITDA LTM / Revenue): 14.5%

Target EV / EBITDA (hist percentile): 14.2x
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 11 424
Net Debt ($m): 2 162
EV (Enterprise Value): 13 586
EBITDA LTM (млн $): 589
EV / LTM EBITDA: 23.1x
Price to Book: 4.5x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2026-01-21businesswire.com

Charles River Laboratories Schedules Fourth-Quarter 2025 Earnings and 2026 Guidance Release and Conference Call

2026-01-21businesswire.com

Charles River Enters Manufacturing Collaboration with Gazi University

2026-01-04globenewswire.com

TLX 5-DAY DEADLINE ALERT: Hagens Berman Urges Telix Investors to Act by Jan. 9 in Class Action Suit Over SEC Subpoena & FDA CRL on Manufacturing Failures

2026-01-03prnewswire.com

TLX 6-DAY DEADLINE ALERT: Hagens Berman Urges Telix Investors to Act by Jan. 9 in Class Action Suit Over SEC Subpoena & FDA CRL on Manufacturing Failures

2026-01-02globenewswire.com

TLX 7-DAY DEADLINE ALERT: Hagens Berman Urges Telix Investors to Act by Jan. 9 Over Alleged Dual Regulatory Failures: SEC Subpoena & FDA CRL on CMC/Supply Chain

2026-01-02zacks.com

Corcept Tanks on FDA's CRL to Relacorilant NDA in Hypercortisolism

2026-01-01prnewswire.com

21% TLX PLUNGE: Hagens Berman Urges Telix Investors to Act by Jan. 9 in Class Action Suit Over SEC Subpoena & FDA CRL on Manufacturing Failures

2025-12-31globenewswire.com

TLX CLASS ACTION DEADLINE: Hagens Berman Urges Telix Investors to Act by Jan. 9 Over Alleged Dual Regulatory Failures: SEC Subpoena & FDA CRL on CMC/Supply Chain

2025-12-29globenewswire.com

TLX 11-DAY DEADLINE ALERT: Hagens Berman Urges Telix (TLX) Investors to Act by Jan. 9 Over Alleged Dual Regulatory Failures: SEC Subpoena & FDA CRL on CMC/Supply Chain

2025-12-27prnewswire.com

21% TLX PLUNGE: Hagens Berman Urges Telix Investors to Act by Jan. 9 in Class Action Suit Over SEC Subpoena & FDA CRL on Manufacturing Failures
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-27 2025-06-28 2024-12-28 2024-09-28 2024-06-29 2024-03-30 2023-12-31 2023-09-30 2023-07-01 2023-04-01 2022-12-31 2022-09-24 2021-12-31 2020-12-31
symbol CRL CRL CRL CRL CRL CRL CRL CRL CRL CRL CRL CRL CRL CRL
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-05 2025-08-06 2024-11-06 2024-08-07 2024-05-09 2023-11-08 2023-08-09 2023-05-11 2022-11-02
acceptedDate 2025-11-05 09:12:06 2025-08-06 09:07:31 2025-02-19 09:07:49 2024-11-06 09:16:46 2024-08-07 09:15:54 2024-05-09 09:17:54 2024-02-14 09:19:45 2023-11-08 09:06:25 2023-08-09 09:09:28 2023-05-11 09:08:55 2023-02-22 09:17:29 2022-11-02 16:13:44 2022-02-16 16:14:01 2021-02-17 16:28:20
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 1 005M 1 032M 4 050M 1 010M 1 026M 1 012M 4 129M 1 027M 1 060M 1 029M 3 976M 989M 3 540M 2 924M
costOfRevenue 666M 675M 2 718M 661M 691M 691M 2 627M 665M 661M 652M 2 513M 619M 2 206M 1 850M
grossProfit 339M 357M 1 332M 349M 335M 320M 1 503M 362M 399M 378M 1 463M 370M 1 335M 1 074M
grossProfitRatio 0.337 0.346 0.346 0.327 0.317 0.352 0.376 0.367 0.374
researchAndDevelopmentExpenses 0 0 0 0 0 0 0 0 0 0 0 0 0 0
generalAndAdministrativeExpenses 0 0 0 0 0 0 0 0 0 0 0 0 0 0
sellingAndMarketingExpenses 0 0 0 0 0 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 178M 192M 751M 199M 166M 177M 748M 176M 200M 175M 665M 184M 620M 529M
otherExpenses 27M 65M 353M 0 -2M 6M 137M -6M -3M 35M 147M 36M 125M 112M
operatingExpenses 205M 257M 1 104M 199M 166M 177M 885M 210M 234M 210M 812M 219M 745M 641M
costAndExpenses 871M 932M 3 823M 860M 857M 869M 3 512M 875M 895M 861M 3 325M 838M 2 950M 2 491M
interestIncome 1M 1M 9M 2M 3M 2M 5M 1M 1M 806 000 780 000 122 000 652 000 834 000
interestExpense 25M 30M 126M 30M 33M 35M 137M 34M 35M 34M 59M 11M 74M 86M
depreciationAndAmortization 85M 120M 362M 88M 86M 85M 314M 79M 78M 75M 304M 58M 266M 235M
ebitda 198M 221M 581M 210M 239M 228M 1 032M 225M 241M 242M 986M 209M 820M 768M
ebitdaratio 0.197 0.214 0.208 0.249 0.226 0.22 0.228 0.236 0.211
operatingIncome 134M 100M 227M 117M 170M 143M 617M 152M 165M 168M 651M 151M 590M 433M
operatingIncomeRatio 0.133 0.097 0.116 0.165 0.141 0.148 0.156 0.163 0.153
totalOtherIncomeExpensesNet -47M -29M -134M -26M -32M -44M -36M -6M -3M -37M -28M -28M -109M 14M
incomeBeforeTax 87M 71M 93M 91M 120M 99M 581M 113M 129M 131M 623M 123M 481M 447M
incomeBeforeTaxRatio 0.087 0.069 0.09 0.117 0.098 0.11 0.121 0.127 0.124
incomeTaxExpense 32M 19M 68M 21M 25M 25M 101M 25M 29M 27M 130M 25M 82M 82M
netIncome 54M 52M 10M 69M 90M 67M 475M 87M 97M 103M 486M 96M 391M 364M
netIncomeRatio 0.054 0.051 0.068 0.088 0.067 0.085 0.092 0.1 0.098
eps 1.11 1.06 0.2 1.34 1.75 1.42 9.27 1.7 1.89 2.02 9.57 1.9 7.77 7.35
epsdiluted 1.1 1.06 1.33 1.74 1.41 1.69 1.89 2.01 1.88
weightedAverageShsOut 49M 49M 51M 51M 52M 51M 51M 51M 51M 51M 51M 51M 50M 50M
weightedAverageShsOutDil 49M 49M 52M 52M 52M 52M 51M 52M 51M 51M 51M 51M 51M 51M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-19 2024-02-14 2023-02-22 2022-02-16 2021-02-17
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome -118M -132M -59M -73M -86M
ebit 219M 718M 682M 555M 534M
nonOperatingIncomeExcludingInterest 8M -101M -31M 35M -101M
netIncomeFromContinuingOperations 25M 480M 493M 399M 365M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome 10M 475M 486M 391M 364M
epsDiluted 0.2 9.22 9.48 7.6 7.2

Balance Sheet Statement

Property 2025 q4 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-12-02 2025-09-27 2025-06-28 2024-12-28 2024-09-28 2024-06-29 2024-03-30 2023-12-31 2023-09-30 2023-07-01 2023-04-01 2022-12-31 2022-09-24 2021-12-31 2020-12-31
symbol CRL CRL CRL CRL CRL CRL CRL CRL CRL CRL CRL CRL CRL CRL CRL
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2022-11-02 2025-11-05 2025-08-06 2024-11-06 2024-08-07 2024-05-09 2023-11-08 2023-08-09 2023-05-11 2022-11-02
acceptedDate 2022-11-02 07:30:51 2025-11-05 09:12:06 2025-08-06 09:07:31 2025-02-19 09:07:49 2024-11-06 09:16:46 2024-08-07 09:15:54 2024-05-09 09:17:54 2024-02-14 09:19:45 2023-11-08 09:06:25 2023-08-09 09:09:28 2023-05-11 09:08:55 2023-02-22 09:17:29 2022-11-02 16:13:44 2022-02-16 16:14:01 2021-02-17 16:28:20
calendarYear 2025 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q4 Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 241M 208M 183M 195M 210M 180M 337M 277M 157M 200M 202M 234M 194M 245M 228M
shortTermInvestments 0 0 0 0 0 0 0 0 0 0 0 0 950 000 0 1M
cashAndShortTermInvestments 241M 208M 183M 195M 210M 180M 337M 277M 157M 200M 202M 234M 195M 246M 229M
netReceivables 643M 734M 768M 721M 754M 762M 787M 780M 799M 801M 788M 752M 778M 650M 618M
inventory 199M 303M 280M 279M 336M 349M 361M 380M 293M 285M 263M 256M 262M 199M 186M
otherCurrentAssets 191M 287M 240M 106M 194M 209M 183M 83M 93M 113M 92M 108M 181M 0 3M
totalCurrentAssets 1 274M 1 532M 1 470M 1 403M 1 495M 1 499M 1 668M 1 609M 1 444M 1 505M 1 448M 1 439M 1 415M 1 274M 1 201M
propertyPlantEquipmentNet 1 584M 1 966M 1 992M 2 017M 2 025M 2 000M 2 003M 2 034M 1 901M 1 927M 1 903M 1 857M 1 754M 1 584M 1 303M
goodwill 2 712M 2 922M 2 936M 2 847M 3 125M 3 080M 3 070M 3 095M 2 885M 2 917M 2 902M 2 850M 2 776M 2 712M 1 809M
intangibleAssets 80M 571M 602M 723M 778M 800M 828M 864M 886M 930M 958M 955M 968M 1 061M 788M
goodwillAndIntangibleAssets 2 792M 3 493M 3 539M 3 570M 3 903M 3 880M 3 898M 3 959M 3 771M 3 846M 3 860M 3 805M 3 744M 3 773M 2 597M
longTermInvestments 0 196M 216M 218M 236M 233M 245M 244M 302M 300M 294M 312M 290M 201M 222M
taxAssets 40M 37M 47M 42M 38M 36M 37M 40M 34M 39M 41M 41M 40M 40M 38M
otherNonCurrentAssets 1 334M 289M 296M 278M 307M 300M 302M 309M 155M 155M 154M 148M 140M 152M 131M
totalNonCurrentAssets 5 750M 5 982M 6 091M 6 125M 6 509M 6 449M 6 485M 6 586M 6 163M 6 268M 6 251M 6 164M 5 967M 5 750M 4 290M
otherAssets 0 0 0 0 0 0 0 0 0 0 0 0 1000 0 0
totalAssets 7 024M 7 514M 7 561M 7 528M 8 004M 7 948M 8 153M 8 195M 7 607M 7 772M 7 699M 7 603M 7 383M 7 024M 5 491M
accountPayables 198M 170M 146M 140M 136M 133M 130M 169M 136M 140M 120M 206M 182M 198M 122M
shortTermDebt 3M 3M 0 0 0 3M 3M 0 422M 412M 0 0 47M 101 000 47M
taxPayables 0 0 0 0 0 35M 34M 39M 45M 45M 38M 0 47M 26M 25M
deferredRevenue 220M 238M 268M 248M 252M 247M 256M 242M 250M 257M 262M 264M 328M 220M 250M
otherCurrentLiabilities 613M 712M 666M 373M 624M 529M 566M 431M 185M 199M 599M 402M 457M 307M 217M
totalCurrentLiabilities 1 033M 1 122M 1 080M 994M 1 012M 948M 955M 1 055M 994M 1 008M 981M 1 092M 1 014M 1 033M 840M
longTermDebt 2 917M 2 629M 2 786M 2 240M 2 731M 2 811M 2 632M 2 647M 2 905M 3 080M 3 162M 2 708M 3 306M 2 917M 1 901M
deferredRevenueNonCurrent 0 42M 0 0 28M 29M 32M 0 29M 30M 29M 0 24M 21M 19M
deferredTaxLiabilitiesNonCurrent 240M 123M 109M 107M 168M 165M 180M 191M 185M 207M 212M 216M 196M 240M 217M
otherNonCurrentLiabilities 2 978M 147M 185M 195M 265M 251M 649M 223M 143M 148M 158M 175M 3 140M -31M 186M
totalNonCurrentLiabilities 3 399M 2 941M 3 081M 3 026M 3 164M 3 228M 3 494M 3 481M 3 262M 3 465M 3 561M 3 488M 3 697M 3 399M 2 507M
otherLiabilities 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 253M 469M 454M 484M 433M 429M 446M 419M 390M 402M 418M 390M 443M 289M 212M
totalLiabilities 4 432M 4 063M 4 161M 4 020M 4 176M 4 175M 4 449M 4 536M 4 256M 4 472M 4 543M 4 579M 4 711M 4 432M 3 347M
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
commonStock 505 000 514 000 513 000 511 000 517 000 517 000 515 000 513 000 514 000 513 000 512 000 509 000 510 000 505 000 498 000
retainedEarnings 981M 1 944M 1 890M 1 812M 2 123M 2 054M 1 960M 1 887M 1 720M 1 633M 1 536M 1 433M 1 280M 981M 625M
accumulatedOtherComprehensiveIncomeLoss -165M -192M -166M -317M -193M -270M -250M -196M -268M -208M -239M -262M -396M -165M -139M
othertotalStockholdersEquity 1 718M 1 652M 1 629M 1 852M 1 938M 1 930M 1 853M 1 826M 1 811M 1 742M
totalStockholdersEquity 2 535M 3 405M 3 353M 3 462M 3 782M 3 723M 3 640M 3 597M 3 306M 3 252M 3 109M 2 976M 2 627M 2 535M 2 115M
totalEquity 2 535M 3 451M 3 400M 3 508M 3 823M 3 773M 3 704M 3 659M 3 351M 3 300M 3 157M 3 024M 2 627M 2 592M 2 144M
totalLiabilitiesAndStockholdersEquity 6 967M 7 514M 7 561M 8 004M 7 948M 8 153M 7 607M 7 772M 7 699M 7 383M
minorityInterest 0 45M 46M 47M 41M 50M 63M 62M 45M 48M 48M 47M 0 57M 29M
totalLiabilitiesAndTotalEquity 6 967M 7 514M 7 561M 7 528M 8 004M 7 948M 8 153M 8 195M 7 607M 7 772M 7 699M 7 603M 7 383M 7 024M 5 491M
totalInvestments 0 196M 216M 218M 236M 233M 245M 244M 302M 300M 294M 312M 291M 201M 223M
totalDebt 2 919M 2 631M 2 786M 2 724M 2 759M 2 841M 3 081M 3 066M 2 905M 3 080M 3 162M 3 097M 3 353M 3 206M 2 160M
netDebt 2 678M 2 424M 2 603M 2 529M 2 549M 2 662M 2 744M 2 790M 2 747M 2 880M 2 960M 2 863M 3 159M 2 964M 1 932M
link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link
filingDate 2025-02-19 2024-02-14 2023-02-22 2022-02-16 2021-02-17
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 509M 552M 548M 643M 618M
otherReceivables 212M 228M 204M 8M 0
prepaids 103M 88M 89M 178M 165M
totalPayables 140M 169M 206M 224M 147M
otherPayables 0 0 0 26M 25M
accruedExpenses 232M 213M 220M 246M 150M
capitalLeaseObligationsCurrent 0 0 0 36M 28M
capitalLeaseObligationsNonCurrent 484M 419M 390M 253M 185M
treasuryStock 0 0 0 0 0
additionalPaidInCapital 1 966M 1 906M 1 805M 1 718M 1 628M
otherTotalStockholdersEquity 0 0 0 0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-27 2025-06-28 2024-12-28 2024-09-28 2024-06-29 2024-03-30 2023-12-31 2023-09-30 2023-07-01 2023-04-01 2022-12-31 2022-09-24 2021-12-31 2020-12-31
symbol CRL CRL CRL CRL CRL CRL CRL CRL CRL CRL CRL CRL CRL CRL
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-05 2025-08-06 2024-11-06 2024-08-07 2024-05-09 2023-11-08 2023-08-09 2023-05-11 2022-11-02
acceptedDate 2025-11-05 09:12:06 2025-08-06 09:07:31 2025-02-19 09:07:49 2024-11-06 09:16:46 2024-08-07 09:15:54 2024-05-09 09:17:54 2024-02-14 09:19:45 2023-11-08 09:06:25 2023-08-09 09:09:28 2023-05-11 09:08:55 2023-02-22 09:17:29 2022-11-02 16:13:44 2022-02-16 16:14:01 2021-02-17 16:28:20
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome 56M 53M 25M 70M 90M 73M 480M 88M 99M 104M 493M 98M 399M 365M
depreciationAndAmortization 85M 120M 362M 88M 86M 85M 314M 79M 78M 77M 304M 75M 266M 235M
deferredIncomeTax 26M -22M -67M -13M -12M -987 000 -51M -12M -5M -12M -36M -12M -24M -133 000
stockBasedCompensation 23M 17M 70M 19M 17M 17M 72M 23M 16M 13M 74M 22M 71M 56M
changeInWorkingCapital -5M 11M -30M 71M -11M -48M -102M 2M -51M -92M -153M -65M 43M -26M
accountsReceivables 27M 11M 22M 17M 18M -17M -33M -11M -14M -34M -151M 0 -27M -86M
inventory -31M 8M 17M 4M 4M 6M -62M -11M -24M -9M -79M -13M -25M -18M
accountsPayables 25M -9M -14M -659 000 2M -9M -20M -2M 16M -41M -3M -25M 45M 748 000
otherWorkingCapital -25M 1M -54M 51M -36M -28M 14M 26M -29M -8M 79M -27M 50M 77M
otherNonCashItems 29M 26M 375M 15M 188M 212M -29M 25M 11M 18M -62M 16M 6M -84M
netCashProvidedByOperatingActivities 214M 205M 735M 252M 194M 130M 684M 205M 148M 109M 620M 133M 761M 547M
investmentsInPropertyPlantAndEquipment -36M -35M -233M -39M -39M -79M -319M -66M -67M -107M -325M -72M -229M -167M
acquisitionsNet -17M 0 -5M 0 -5M 0 -195M 66M -75M -50M -120M 0 -1 170M -419M
purchasesOfInvestments -4M -3M -53M -10M -22M -14M -54M -14M -10M -13M -158M -21M -46M -27M
salesMaturitiesOfInvestments 4M 504 000 42M 27M 5M 8M 7M 1M 990 000 2M 5M 3M 7M 11M
otherInvestingActivites 20M 243 000 12 000 -87 000 -283 000 -67M 75M -960 000 -2M
netCashUsedForInvestingActivites -34M -37M -21M -62M -86M -80M -77M -169M -92M
debtRepayment -146M -191M -94M -255M -8M -214M -160M -157M -668M
commonStockIssued 2000 0 0 0 22M 4M 0 12M 0
commonStockRepurchased -93 000 -7M -119M -101M -9M -9M -24M -38 000 -5M -19M -39M -24 000 -41M -24M
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites -6M -28M -13M -22M -2M 51M 93M 190M 617M
netCashUsedProvidedByFinancingActivities -153M -227M -208M -286M 18M -163M -71M 25M -52M
effectOfForexChangesOnCash -3M 13M -17M 8M -3M -8M 8M -6M -163 000 2M 26M -30 000 18M 794 000
netChangeInCash 24M -47M -79M 32M -158M 55M 43M -43M -114 000 -32M -5M -11M 13M -7M
cashAtEndOfPeriod 209M 185M 206M 212M 180M 337M 284M 166M 209M 209M 241M 196M 246M 233M
cashAtBeginningOfPeriod 185M 232M 284M 180M 337M 283M 241M 209M 209M 241M 246M 207M 233M 240M
operatingCashFlow 214M 205M 735M 252M 194M 130M 684M 205M 148M 109M 620M 133M 761M 547M
capitalExpenditure -36M -35M -233M -39M -39M -79M -319M -66M -67M -107M -325M -72M -229M -167M
freeCashFlow 178M 169M 502M 213M 154M 51M 365M 140M 81M 3M 295M 60M 532M 380M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-19 2024-02-14 2023-02-22 2022-02-16 2021-02-17
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities 5M -2M -9M 264 000 -1M
netCashProvidedByInvestingActivities -245M -563M -608M -1 438M -602M
netDebtIssuance -412M -75M 20M 670M 31M
longTermNetDebtIssuance -412M -75M 20M 670M 31M
shortTermNetDebtIssuance 0 0 0 0 0
netStockIssuance -119M -24M -39M -41M -24M
netCommonStockIssuance -119M -24M -39M -41M -24M
commonStockIssuance 0 0 0 0 0
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities -20M 14M -24M 43M 41M
netCashProvidedByFinancingActivities -551M -86M -42M 673M 47M
incomeTaxesPaid 126M 90M 76M 75M 60M
interestPaid 123M 132M 101M 71M 72M

Earning call transcript

2025 q3
2025-11-05 ET (fiscal 2025 q3)
2025 q2
2025-08-06 ET (fiscal 2025 q2)
2025 q1
2025-05-07 ET (fiscal 2025 q1)
2024 q4
2025-02-19 ET (fiscal 2024 q4)
2024 q3
2024-11-06 ET (fiscal 2024 q3)
2024 q2
2024-08-07 ET (fiscal 2024 q2)
2024 q1
2024-05-09 ET (fiscal 2024 q1)
2023 q4
2024-02-14 ET (fiscal 2023 q4)
2023 q3
2023-11-08 ET (fiscal 2023 q3)
2023 q2
2023-08-09 ET (fiscal 2023 q2)
2023 q1
2023-05-11 ET (fiscal 2023 q1)
2022 q4
2023-02-22 ET (fiscal 2022 q4)
2022 q3
2022-11-02 ET (fiscal 2022 q3)
2022 q2
2022-08-03 ET (fiscal 2022 q2)
2022 q1
2022-05-04 ET (fiscal 2022 q1)

SEC forms

Show financial reports only

SEC form 8
2026-01-13 13:10 ET
Charles River Laboratories International published news for 2025 q4
SEC form 10
2025-11-05 09:12 ET
Charles River Laboratories International reported for 2025 q3
SEC form 8
2025-11-05 07:16 ET
Charles River Laboratories International reported for 2025 q3
SEC form 8
2025-11-05 07:16 ET
Charles River Laboratories International published news for 2025 q3
SEC form 10
2025-08-06 13:07 ET
Charles River Laboratories International reported for 2025 q2
SEC form 8
2025-08-06 11:08 ET
Charles River Laboratories International reported for 2025 q2
SEC form 8
2025-08-06 11:08 ET
Charles River Laboratories International published news for 2025 q2
SEC form 10
2025-05-07 13:09 ET
Charles River Laboratories International reported for 2025 q1
SEC form 8
2025-05-07 11:08 ET
Charles River Laboratories International reported for 2025 q1
SEC form 8
2025-05-07 11:08 ET
Charles River Laboratories International published news for 2025 q1
SEC form 10
2025-05-07 00:00 ET
Charles River Laboratories International reported for 2025 q1
SEC form 10
2025-02-19 14:07 ET
Charles River Laboratories International published news for 2024 q4
SEC form 10
2025-02-19 00:00 ET
Charles River Laboratories International reported for 2024 q4
SEC form 8
2025-02-19 00:00 ET
Charles River Laboratories International published news for 2024 q4
SEC form 8
2025-02-19 00:00 ET
Charles River Laboratories International published news for 2024 q4
SEC form 10
2024-11-06 09:16 ET
Charles River Laboratories International reported for 2024 q3
SEC form 8
2024-11-06 07:21 ET
Charles River Laboratories International published news for 2024 q3
SEC form 8
2024-11-06 07:21 ET
Charles River Laboratories International published news for 2024 q3
SEC form 10
2024-08-07 09:15 ET
Charles River Laboratories International reported for 2024 q2
SEC form 8
2024-08-07 07:21 ET
Charles River Laboratories International published news for 2024 q2
SEC form 8
2024-08-07 07:21 ET
Charles River Laboratories International published news for 2024 q2
SEC form 10
2024-08-07 00:00 ET
Charles River Laboratories International published news for 2024 q2
SEC form 8
2024-05-09 00:00 ET
Charles River Laboratories International published news for 2024 q1
SEC form 8
2024-05-09 00:00 ET
Charles River Laboratories International published news for 2024 q1
SEC form 10
2024-05-09 00:00 ET
Charles River Laboratories International reported for 2024 q1
SEC form 8
2024-02-14 00:00 ET
Charles River Laboratories International published news for 2023 q4
SEC form 8
2024-02-14 00:00 ET
Charles River Laboratories International published news for 2023 q4
SEC form 10
2024-02-14 00:00 ET
Charles River Laboratories International reported for 2023 q4
SEC form 10
2023-11-08 09:06 ET
Charles River Laboratories International reported for 2023 q3
SEC form 8
2023-11-08 07:30 ET
Charles River Laboratories International published news for 2023 q3
SEC form 10
2023-11-08 00:00 ET
Charles River Laboratories International reported for 2023 q3
SEC form 10
2023-08-09 09:09 ET
Charles River Laboratories International reported for 2023 q2
SEC form 6
2023-08-09 07:30 ET
Charles River Laboratories International published news for 2023 q2
SEC form 10
2023-08-09 00:00 ET
Charles River Laboratories International reported for 2023 q2
SEC form 8
2023-08-09 00:00 ET
Charles River Laboratories International published news for 2023 q2
SEC form 10
2023-05-11 09:08 ET
Charles River Laboratories International reported for 2023 q1
SEC form 6
2023-05-11 07:30 ET
Charles River Laboratories International published news for 2023 q1
SEC form 10
2023-05-11 00:00 ET
Charles River Laboratories International reported for 2023 q1
SEC form 8
2023-05-11 00:00 ET
Charles River Laboratories International published news for 2023 q1
SEC form 10
2023-02-22 09:17 ET
Charles River Laboratories International reported for 2022 q4
SEC form 6
2023-02-22 07:30 ET
Charles River Laboratories International published news for 2022 q4
SEC form 10
2023-02-22 00:00 ET
Charles River Laboratories International reported for 2022 q4
SEC form 8
2023-02-22 00:00 ET
Charles River Laboratories International published news for 2022 q4
SEC form 6
2022-12-06 17:30 ET
Charles River Laboratories International published news for 2022 q3
SEC form 6
2022-11-30 10:01 ET
Charles River Laboratories International published news for 2022 q3
SEC form 10
2022-11-02 16:13 ET
Charles River Laboratories International published news for 2022 q3
SEC form 6
2022-11-02 07:30 ET
Charles River Laboratories International published news for 2022 q3
SEC form 8
2022-11-02 00:00 ET
Charles River Laboratories International published news for 2022 q3
SEC form 10
2022-11-02 00:00 ET
Charles River Laboratories International reported for 2022 q3
SEC form 10
2022-08-03 15:59 ET
Charles River Laboratories International published news for 2022 q2
SEC form 6
2022-08-03 07:30 ET
Charles River Laboratories International published news for 2022 q2
SEC form 8
2022-08-03 00:00 ET
Charles River Laboratories International published news for 2022 q2
SEC form 10
2022-08-03 00:00 ET
Charles River Laboratories International reported for 2022 q2
SEC form 6
2022-06-08 07:00 ET
Charles River Laboratories International published news for 2022 q1
SEC form 6
2022-05-12 17:07 ET
Charles River Laboratories International published news for 2022 q1
SEC form 10
2022-05-04 16:45 ET
Charles River Laboratories International published news for 2022 q1
SEC form 6
2022-05-04 07:30 ET
Charles River Laboratories International published news for 2022 q1
SEC form 8
2022-05-04 00:00 ET
Charles River Laboratories International published news for 2022 q1
SEC form 10
2022-05-04 00:00 ET
Charles River Laboratories International reported for 2022 q1
SEC form 6
2022-03-30 08:32 ET
Charles River Laboratories International published news for 2021 q4
SEC form 6
2022-03-28 08:55 ET
Charles River Laboratories International published news for 2021 q4
SEC form 10
2022-02-16 16:14 ET
Charles River Laboratories International published news for 2021 q4
SEC form 6
2022-02-16 07:30 ET
Charles River Laboratories International published news for 2021 q4
SEC form 10
2022-02-16 00:00 ET
Charles River Laboratories International published news for 2021 q4
SEC form 8
2022-02-16 00:00 ET
Charles River Laboratories International published news for 2021 q4
SEC form 6
2022-01-11 07:19 ET
Charles River Laboratories International published news for 2021 q4
SEC form 6
2021-12-27 16:42 ET
Charles River Laboratories International published news for 2021 q3
SEC form 6
2021-12-15 16:35 ET
Charles River Laboratories International published news for 2021 q3
SEC form 6
2021-11-12 08:09 ET
Charles River Laboratories International published news for 2021 q3
SEC form 6
2021-11-09 07:37 ET
Charles River Laboratories International published news for 2021 q3
SEC form 10
2021-11-03 16:01 ET
Charles River Laboratories International published news for 2021 q3
SEC form 6
2021-11-03 07:30 ET
Charles River Laboratories International published news for 2021 q3
SEC form 8
2021-11-03 00:00 ET
Charles River Laboratories International published news for 2021 q3
SEC form 10
2021-11-03 00:00 ET
Charles River Laboratories International published news for 2021 q3
SEC form 10
2021-08-04 16:08 ET
Charles River Laboratories International published news for 2021 q2
SEC form 6
2021-08-04 07:30 ET
Charles River Laboratories International published news for 2021 q2
SEC form 8
2021-08-04 00:00 ET
Charles River Laboratories International published news for 2021 q2
SEC form 10
2021-08-04 00:00 ET
Charles River Laboratories International published news for 2021 q2
SEC form 6
2021-05-18 16:16 ET
Charles River Laboratories International published news for 2021 q1
SEC form 6
2021-05-10 17:19 ET
Charles River Laboratories International published news for 2021 q1
SEC form 10
2021-05-04 16:01 ET
Charles River Laboratories International published news for 2021 q1
SEC form 6
2021-05-04 07:30 ET
Charles River Laboratories International published news for 2021 q1
SEC form 8
2021-05-04 00:00 ET
Charles River Laboratories International published news for 2021 q1
SEC form 10
2021-05-04 00:00 ET
Charles River Laboratories International published news for 2021 q1
SEC form 6
2021-04-23 16:01 ET
Charles River Laboratories International published news for 2021 q1
SEC form 6
2021-03-29 17:18 ET
Charles River Laboratories International published news for 2020 q4
SEC form 6
2021-03-26 12:39 ET
Charles River Laboratories International published news for 2020 q4
SEC form 6
2021-03-23 16:42 ET
Charles River Laboratories International published news for 2020 q4
SEC form 6
2021-03-09 08:59 ET
Charles River Laboratories International published news for 2020 q4
SEC form 10
2021-02-17 16:28 ET
Charles River Laboratories International published news for 2020 q4
SEC form 6
2021-02-17 16:03 ET
Charles River Laboratories International published news for 2020 q4
SEC form 6
2021-02-17 07:30 ET
Charles River Laboratories International published news for 2020 q4
SEC form 10
2020-11-09 16:44 ET
Charles River Laboratories International published news for 2020 q3
SEC form 6
2020-10-29 07:38 ET
Charles River Laboratories International published news for 2020 q3
SEC form 6
2020-10-19 17:25 ET
Charles River Laboratories International published news for 2020 q3